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ABSTRACT
Background and Objectives: The prognostic value of biochemical markers and the resolution of ST-segment elevation on 
electrocardiogram are well established. However, how a combination of these two tools affects the evaluation of risk stratifi-
cation has not yet been evaluated. Subjects and Methods: Between January 2006 and June 2008, 178 consecutive patients 
treated with primary percutaneous coronary interventions after ST-segment elevation myocardial infarctions (STEMI) were 
analyzed at two coronary care units. Patients were divided into the following three groups according to ST-segment resolu-
tion: complete (≥70% depression of the elevated ST-segment, n=63), partial (30% to 70%, n=90), and incomplete (<30%, 
n=25). Demographic data, including history, electrocardiography, biochemical markers, initial ejection fraction, and angio-
graphic findings were also evaluated. Results: There were 7 deaths, 3 repeated myocardial infarctions, and 17 readmissions 
for worsening heart failure during six months of follow-up. In a multivariate analysis to predict clinical outcomes, ejection frac-
tion {hazard ratio (HR): 0.83 (0.76-0.91), p<0.01}, high-sensitivity C-reactive protein {HR: 1.15 (1.05-1.26), p<0.05}, and the 
degree of ST-segment resolution {HR: 0.96 (0.93-0.09), p<0.05} were independently associated with clinical outcomes. Accord-
ing to the Cox-proportional hazards model, the addition of ST-segment resolution markedly improved the prognostic utility 
of the model containing biochemical markers and ejection fraction. Conclusion: Assessment of biomarkers upon admis-
sion and ST-segment resolution are strong predictors of clinical outcomes. The combination of these data provides additive 
information about prognosis at an early point in the disease progression and further improves risk stratification for STEMI. 
(Korean Circ J 2011;41:372-378)
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Introduction
Early risk stratification is essential in the management of 
patients with suspected or confirmed acute coronary synd-
rome. Traditionally, risk stratification involves an evaluation 
of medical history, a physical examination, and electrocardio-
graphy (ECG) upon admission. In recent years, additional 
variables for early risk stratification in patients with ST elev-
ation myocardial infarction (STEMI) have been identified, 
and include the elevation of cardiac biochemical markers. For 
example, the myocardial release of troponin I (TnI) and N-ter-
minal pro-B-type natriuretic peptide (NT-proBNP) represent 
sensitive serum markers for minimal myocardial injury. When 
present, these markers are associated with an increased likeli-
hood of a cardiac event.
1) The elevation of another marker, 
high-sensitivity C-reactive protein (hsCRP), upon admission 
with STEMI is associated with an increased risk of compli-
cations both during hospitalization and after discharge.
2) These 
biochemical markers are noninvasive indicators of the risk of Jong Shin Woo, et al.   373
first or recurrent cardiovascular events and also predict the 
success of therapeutic and preventive interventions.
1) Thus, 
several studies have demonstrated the independent progno-
stic value of elevated TnI, NT-proBNP, or hsCRP at admission 
in patients with STEMI.
3-9) Additionally, in patients treated for 
STEMI, early ST-segment resolution has been associated with 
a better outcome based on improved early infarct-related ar-
tery patency, smaller infarct size, and less impairment of left 
ventricular function.
10-12)
However, the combination of these two early available tools 
for predicting risk soon after a patient’s presentation has not 
been evaluated. To address these issues, we retrospectively 
assessed the clinical characteristics and follow-up outcomes 
of consecutive patients who received primary percutaneous 
coronary intervention (PCI) after STEMI. The aim of this stu-
dy was to evaluate the combined effect of using multiple bio-
chemical markers and ST-segment resolution assessments for 
early risk stratification in patients with STEMI and treated 
by PCI.
Subjects and Methods
Study participants
Between January 2006 and June 2008, 178 consecutive pa-
tients who presented with their first STEMI and were subse-
quently treated with primary PCI were enrolled in the study, 
which took place at two coronary care units at the Kyung Hee 
University Hospital, Seoul, Korea. All patients were treated 
according to the standard of care for STEMI and underwent 
primary PCI. The diagnostic work-up in all patients consist-
ed of history, 12-lead ECG, blood chemistries, and a two-di-
mensional (2D) echocardiography. The inclusion criteria 
were as follows: 1) presentation within 12 hours of symptom 
onset; 2) chest pain lasting ≥30 minutes and resistant to ni-
trates; and 3) ≥0.2 mV ST-segment elevation in at least two 
contiguous leads on 12-lead ECG. The exclusion criteria were 
as follows: 1) prior myocardial infarction, defined by pre-exist-
ing pathologic Q-wave; 2) non-ST elevation myocardial in-
farction; and 3) thrombolytic therapy taken instead of PCI. Pa-
tents with infectious disease, collagen disease, malignant dise-
ase, or severe hepatic or renal failure were also excluded. Ini-
tial clinical demographic data, including Killip classification, 
symptom-to-balloon times, door-to-balloon times, and pre- 
and post-thrombolysis in myocardial infarction (TIMI) flow 
grades were evaluated. All patients included in the study sam-
ple provided written informed consent for all procedures 
and our institutional review board approved this research.
Electrocardiographic and echocardiographic  
assessment
For all 178 patients, a standard 12-lead ECG was obtained 
at initial presentation and at 60 minutes after PCI, and was 
obtained by investigators blinded to the clinical characteris-
tics and coronary angiography findings of the patients. Using 
calipers, the sum of the ST-segment elevation 20 ms after the 
J point was calculated and compared with the baseline ECG. 
The percent resolution of the ST-segment on ECG was cate-
gorized as complete (≥70%), partial (30% to 70%), or incom-
plete (≤30%), as originally described by Schroder et al.
10) In all 
patients, standard echocardiography was performed within 
one hour after coronary intervention. Left ventricular (LV) ej-
ection fraction (EF) was also assessed. 
Biochemical markers
Blood samples used to obtain serum levels of TnI, NT-pro-
BNP, and hsCRP were taken on presentation at the emerg-
ency department of each center. Creatine phosphokinase (CK), 
CK-MB isoenzyme, and TnI levels were measured quantita-
tively at admission, six hours later, and then twice daily over 
the first 48 hours. Levels were detected routinely in the labo-
ratory using commercially available assays (Abbott Immu-
noassay, Abbott Laboratories, Abbott Park, IL, USA). The nor-
mal value of TnI in our institution is 0.5 ng/mL. TnI levels 
≥0.5 ng/mL on admission was used as a serum marker for 
myocardial ischemia. NT-proBNP and hsCRP levels were 
also measured quantitatively at admission. NT-proBNP was 
quantified using a one-step enzyme immunoassay based on 
electrochemiluminescence technology (Elecsys 2010, Roche 
Diagnostics). Finally, hsCRP was determined with the Hita-
chi 717 system (Roche Diagnostics). 
Follow-up and end points
All study participants underwent the implantation of drug-
eluting stents (DES). The choice of the specific type of DES 
{i.e., sirolimus-eluting (Cypher, Cordis, Johnson & Johnson, 
Miami Lakes, FL, USA) or paclitaxel-eluting (Taxus, Boston 
Scientific, Natick, MA, USA) stents} was left to the surgeon’s 
discretion. Patients were prescribed aspirin and clopidogrel 
for at least six months, regardless of DES type. All partici-
pants were followed for at least six months (13.6±3.1 mon-
ths). The outcome events in this study were all cause mortali-
ty, repeated myocardial infarction, and readmission for wor-
sening of heart failure up to six months after PCI. 
Statistical analysis
Statistical analysis was performed using the SPSS package 
for Windows, Version 17.0. Continuous variables are present-
ed as a mean±a standard deviation or median, as appropriate, 
and categorical variables as a percentage. Continuous data 
were compared using one-way analysis of variance among ST-
segment resolution groups. Categorical data were compared 
using the chi-square test. Correlations between two continu-
ous variables were performed using the Pearson correlation 
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logistic regression was performed to check for independent 
variables related to major adverse cardiac events (MACE) re-
ported up to six months of follow-up. The overall MACE-
free survival rates were calculated using the Kaplan-Meier me-
thod, and the differences were determined using the log-rank 
test. The independent effects of variables on prognosis were 
calculated using a Cox proportional hazards regression mo-
del. Additionally, we performed a univariate and multivari-
ate analysis using a Cox proportional hazards regression mo-
del, in which we explored the effects of different combinations 
of biomarkers on patient prognosis. A p<0.05 was consider-
ed statistically significant.
Results
Initial clinical characteristics in each ST-segment 
resolution group
The 178 patients treated with primary PCI were divided into 
the following three groups according to ST-segment resolu-
tion: complete (n=63, 59.9±12.3 years, male 81%), partial 
(n=90, 63.9±10.9 years, male 68%), and incomplete (n=25, 
67.6±13.3 years, male 76%). Baseline characteristics, risk 
factors, LV EF, and biochemical markers at admission are li-
sted in Table 1. Patients in the incomplete resolution group 
were older, had worse Killip classifications, and had signifi-
cantly prolonged symptom-to-door times and door-to-bal-
loon times. Risk factors such as diabetes, hypertension, dys-
lipidemia, smoking history, and ischemic heart disease his-
tory were not different among the three groups. There were 
no significant differences among the groups regarding use of 
medications, such as aspirin, clopidogrel, beta-blockers, an-
giotensin converting enzyme inhibitors, angiotensin recep-
tor blockers, and statins either during admission or after dis-
charge (data not shown). 
Laboratory and echocardiographic findings in each 
ST-segment resolution group
The LV EF was significantly lower in patients with incom-
plete resolution (Table 1). Biochemical markers, such as TnI, 
NT-proBNP, and hsCRP at admission were significantly hi-
gher among patients in the incomplete resolution group, and 
were well correlated with the percent of ST-segment resolu-
tion (r=-0.38, p<0.01; r=-0.41, p<0.01; r=-0.43, p<0.01, res-
pectively). However, the maximal values of CK-MB and TnI 
after PCI were not significantly different among the three gr-
oups (data not shown). 
Angiographic findings and clinical outcomes
As shown in Table 2, there were no differences among the 
3 groups in the number of diseased vessels, location of the cul-
Table 1. Baseline characteristics classified by degree of ST-segment resolution after PCI in patients with ST-segment elevation myocardial 
infarction
Complete (n=63) Partial (n=90) Incomplete (n=25) p
Age (year) 59.9±12.3 63.9±10.9 67.6±13.3 <0.05
Male gender (%) 51 (81) 61 (68) 19 (76) 0.18
sBP (mmHg) 129.3±28.80 120.3±35.10 115.0±28.00 0.10
dBP (mmHg) 76.0±14.2 73.5±18.7 68.5±19.7 0.19
Heart rate (beat/min) 73.4±14.8 79.2±23.7 79.6±21.1 0.19
Killip class (more than II) (%) 10 (16) 41 (45) 16 (64) <0.01
Symptom-to-door times (minute) 209.8±130.8 263.5±171.0 422.3±206.7 <0.01
Door-to-balloon time (minute) 80.6±24.7 96.2±41.3 185.4±74.90 <0.01
Anterior wall MI (%) 34 (54) 48 (53) 15 (60) 0.83
Risk factors (%)
Diabetes 21 (33) 26 (29) 08 (32) 0.84
Dyslipidemia 21 (33) 24 (27) 06 (24) 0.57
Hypertension 36 (57) 23 (65) 15 (60) 0.56
Smoking 41 (65) 54 (60) 15 (60) 0.75
History of IHD 21 (33) 25 (28) 13 (52) 0.07
Ejection fraction 53.5±9.60 47.3±10.3 40.3±9.90 <0.01
Initial TnI (ng/mL) 02.6±12.8 05.9±16.9 16.3±26.2 <0.01
NT-proBNP (pg/mL) 353.9±723.9 1082.5±2205.1 2035.3±1903.0 <0.01
hsCRP (mg/L) 3.5±7.9 4.9±7.6 9.9±9.8 <0.01
Continuous data are presented as the mean value±standard deviation and categorical variables are presented as a percentage. P were calcu-
lated from comparisons across the three groups. PCI: percutaneous coronary intervention, sBP: systolic blood pressure, dBP: diastolic blood 
pressure, MI: myocardial infarction, IHD: ischemic heart disease, TnI: troponin I, NT-proBNP: N-terminal pro-B-type natriuretic peptide, 
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prit artery, type of lesion, or target lesion. Pre- and post-TI-
MI flow grade 0 or 1 was more commonly observed in the in-
complete group, but this finding was not statistically signifi-
cant. The duration of coronary care unit admission in days 
was significantly prolonged in the incomplete group (2.3± 
1.4, 3.2±2.3 and 4.7±2.9, respectively; p<0.05). Three (1.7%) 
patients died before discharge, and another four (2.2%) pa-
tients died during the follow-up period. The in-hospital mor-
tality was only in the incomplete group. 
The all-cause mortality rate increased stepwise according 
to ST-segment resolution status (0%, 1%, and 24%, respecti-
vely; p<0.01). Three patients were re-treated due to repeated 
infarction, as shown in Table 2. During follow-up, 17 patients 
were readmitted for worsening congestive heart failure. The 
readmission rate was 3% (2/63), 10% (9/90), and 24% (6/25) 
in complete, partial, and incomplete ST resolution groups, res-
pectively (p<0.01).
Prognostic values of biochemical markers and 
ST-segment resolution
Using median values, the study sample was divided into two 
groups according to the initial TnI (median=0.38 ng/mL), 
hsCRP (median=2.45 mg/L), and NT-proBNP (median=456 
pg/mL) levels. Kaplan-Meier curves showing MACE-free-sur-
vival based on the biochemical levels and ST-segment resolu-
tions are presented in Fig. 1. There was a significant increas-
ed risk of six-month MACE with increasing baseline circul-
ating levels of either TnI (6%, and 23% for lower and higher 
levels, respectively; p<0.01), hsCRP (6%, and 23% for lower 
and higher levels, respectively; p<0.01), or NT-proBNP (10%, 
and 24% for lower and higher levels, respectively; p<0.05). 
There was also a significant, gradually increased risk of six-
month MACE according to the ST resolution status (5%, 12%, 
and 48% for complete, partial and incomplete ST resolution, 
respectively; p<0.01). 
To evaluate the independent contribution of ST-segment 
Table 2. Angiographic characteristics and outcomes according to degree of ST-segment resolution after PCI in patients with STEMI
Complete (n=63) Partial (n=90) Incomplete (n=25) p
Coronary flow before PCI (%) 0.15
TIMI 0 or 1 46 (73) 68 (75) 23 (92)
TIMI 2 or 3 17 (27) 22 (25) 2 (8)
Coronary flow after PCI (%) 0.11
TIMI 0 or 1 5 (8) 6 (7) 05 (20)
TIMI 2 or 3 58 (92) 84 (93) 20 (80)
No. of diseased vessels (%) 0.48
1 22 (35) 39 (43) 08 (32)
2 20 (32) 29 (36) 10 (40)
3 21 (33) 19 (21) 07 (28)
Culprit artery (%) 0.75
Left main 0 (0) 3 (3) 0 (0)
LAD 31 (49) 50 (55) 13 (52)
LCX 6 (9)  5 (5) 2 (8)
RCA 26 (41)  32 (35) 10 (40)
Lesion type (%) 0.24
A or B1 14 (22)  14 (15) 2 (8)
B2 or C 49 (78)  76 (85) 23 (92)
Target lesion
Stent diameter 03.2±0.5 03.1±0.3 03.3±0.4 0.15
Stent length 25.5±5.1 26.3±5.2 26.0±5.7 0.67
CCU adm (days) 02.3±1.4 03.3±2.3 03.7±2.9 <0.01
In-hospital mortality (%) 0 (0) 0 (0) 3  <0.01
Overall mortality (%) 0 (0) 1 (1) 06 (24) <0.01
Re-infarction (%) 1 (1) 1 (1) 1 (4) 0.61
Re-hospitalization due to CHF (%) 2 (3) 09 (10) 06 (24) <0.01
Continuous data are presented as the mean value±standard deviation and categorical variables are presented as a percentage. P were calculated 
from comparisons across the three groups. PCI: percutaneous coronary intervention, STEMI: ST-segment elevation myocardial infarction, 
TIMI: Thrombolysis in Myocardial Infarction, LAD: left descending artery, LCX: left circumflex artery, RCA: right coronary artery, CCU: 
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resolution to the prediction of clinical outcomes after STEMI, 
multiple regression analysis was performed (Table 3). Variables 
used for this analysis were age, Killip classification, symp-
tom-to-balloon time, door-to-balloon time, LV EF, TnI, hs-
CRP, NT-proBNP, and the degree of ST-segment resolution. 
For multiple regression analysis, univariate analysis was se-
lected for factors showing a p<0.05. The most important pre-
dictors of clinical outcomes after STEMI were the LV EF {ha-
zards ratio (HR): 0.83 (0.76-0.91), p<0.01}, hsCRP {HR: 1.15 
(1.05-1.26), p<0.05}, and the degree of ST-segment resolution 
{HR: 0.96 (0.93-0.09), p<0.05}. The additional benefit of us-
ing ST-segment resolution to predict cardiac events is shown 
in Fig. 2. With regard to the incremental value, ST-segment 
resolution is a good parameter to predict MACE after STEMI. 
However, the addition of biochemical markers markedly im-
proved the prognostic utility of the model containing ST-seg-
ment resolution.
Table 3. Univariate and multivariate predictors of major adverse cardiac events after ST-segment elevation myocardial infarction
Univariate analysis Multivariate analysis
p Hazard ratio (95% Cl) p Hazard ratio (95% Cl)
Age <0.08 1.03 (0.99-1.07) - -
Killip class <0.07 2.18 (0.94-5.05) - -
Sx-to-balloon time <0.07 1.00 (1.00-1.01) - -
Door-to-balloon time <0.01 1.01 (1.00-1.02) <0.57 1.00 (0.99-1.02)
Ejection fraction <0.01 0.90 (0.86-0.94) <0.01 0.83 (0.76-0.91)
Initial TnI <0.05 1.02 (1.00-1.04) <0.19 1.02 (0.99-1.05)
Initial hsCRP <0.01 1.09 (1.04-1.14) <0.05 1.15 (1.05-1.26)
Initial NT-proBNP <0.05 1.01 (1.00-1.02) <0.93 1.00 (1.00-1.00)
Degree of ST resolution <0.01 0.96 (0.94-0.98) <0.05 0.96 (0.93-0.99)
IHD: ischemic heart disease, Sx: symptom, TnI: troponin I, NT-proBNP: N-terminal pro-B-type natriuretic peptide, hsCRP: high-sensitivity 
C-reactive protein
Fig. 1. Kaplan-Meier analysis according to the statuses of TnI (A), hsCRP (B), NT-proBNP (C), and ST resolution (D). Elevated TnI, hsCRP, 
and NT-proBNP at initial presentation showed a significantly higher number of major adverse cardiac events (p<0.01 for all). Patients pre-
senting with incomplete ST segment resolution had a significantly worse clinical outcome over the 6-month follow-up (p<0.01). TnI: troponin I, 
hsCRP: high-sensitivity C-reactive protein, NT-proBNP: N-terminal pro-B-type natriuretic peptide.
1.0
0.8
0.6
0.4
0.2
0.0
1.0
0.8
0.6
0.4
0.2
0.0
1.0
0.8
0.6
0.4
0.2
0.0
1.0
0.8
0.6
0.4
0.2
0.0
Time (days)
Time (days)
Time (days)
Time (days)
C
u
m
 
s
u
r
v
i
v
a
l
C
u
m
 
s
u
r
v
i
v
a
l
C
u
m
 
s
u
r
v
i
v
a
l
C
u
m
 
s
u
r
v
i
v
a
l
0           30          60           90        120         150       180
0           30          60           90        120         150       180
0           30          60           90        120         150       180
0           30          60           90        120         150       180
TnI ≥0.38 ng/mL
NT-proBNP ≥456 pg/mL
hsCRP ≥2.45 mg/L
Incomplete resolution
Partial resolution
p<0.01
p<0.01
p<0.01
p<0.01
TnI <0.38 ng/mL
NT-proBNP <456 pg/mL
hsCRP <2.45mg/L
Complete resolution
A  
C  
B  
D  Jong Shin Woo, et al.   377
Discussion
In this study, initial TnI, NT-proBNP, and hsCRP plasma 
levels were higher in the incomplete ST-segment resolution 
group than in the ST-segment resolution groups, and these 
elevated biomarkers on admission predicted an adverse prog-
nosis over the following six months, especially among patients 
who presented with two or three elevated biomarkers. Fur-
thermore, biochemical markers, such as TnI, NT-proBNP, 
and hsCRP at admission were well correlated with the per-
cent of ST-segment resolution. The combination of these tools 
improved risk stratification in STEMI.
In agreement with previous studies,
13-15) elevated levels of 
TnI, NT-proBNP, and hsCRP were each associated with hi-
gher rates of MACE. Among them, only the hsCRP at initial 
presentation was significantly and independently associated 
with an adverse prognosis over the next six months. This find-
ing suggests that the inflammatory process associated with 
myocardial necrosis may be still ongoing when the degree of 
inflammation in the acute phase increases, as several lines of 
studies have suggested.
16-18) 
By contrast, TnI and NT-proBNP were not independent pre-
dictors of clinical outcomes. This discrepancy with previous 
studies is probably explained by the relatively small sample 
size. However, despite the small sample size, the combination 
of several these markers allowed for a very good prediction of 
clinical outcomes in patients with STEMI treated with PCI 
as shown in Fig. 2. These incremental effects could be expl-
ained by the different pathophysiological mechanisms assess-
ed by these three biomarkers in myocardial ischemia, i.e., el-
evations in troponins indicate myocardial necrosis,
3)13) NT-
proBNP is elevated in response to left ventricular overload,
8)9) 
and hsCRP is a marker of inflammation.
1)2) Multi-marker ap-
proaches to rapidly stratify patients and identify those at risk 
for adverse cardiac outcomes may help in the selection of more 
intense interventional or pharmacological treatment strategies.
In the present study, ST-segment resolution at 60 minutes 
was independently associated with six-month MACE, which 
agrees with the findings of previous studies.
3)10) Another strong 
finding was a positive correlation between ST-segment reso-
lution and the three biochemical makers. We evaluated the 
association between the initial biochemical makers and par-
tial or incomplete ST-segment resolution. In a multivariate 
analysis, elevated hsCRP {HR: 6.29 (2.43-16.30), p<0.01} and 
elevated NT-proBNP {HR: 3.32 (1.29-8.52), p<0.01} were in-
dependently associated with partial or incomplete ST-seg-
ment resolution, but not elevated TnI {HR: 2.47 (0.99-6.20), 
p=0.053}. This finding suggests that high burdens of inflam-
mation and ventricular loads may be associated with a lower 
likelihood of successful epicardial reperfusion. For this rea-
son, the combination of biomarkers and early ST-segment 
resolution improved risk prediction. Biomarkers at admission 
and ST-segment resolution at 60 minutes are strong predic-
tors of clinical outcomes, and the combination of them gives 
additive early information concerning patient prognosis, 
and further improves risk stratification in STEMI.
There are several limitations to the present study. Only a 
small number of patients from two centers were enrolled. The 
possibility of selection bias and low statistical power must 
therefore be considered when interpreting our findings. How-
ever, we demonstrated that elevated levels of biochemical mar-
kers were each associated with higher rates of clinical out-
comes, as has been demonstrated by previous studies.
1)7)11)15) 
We also showed the powerful prognostic value of the combin-
ation of biomarkers at admission and ST-segment resolution 
at 60 minutes. 
Another weak point of this study is that it was a retrospec-
tive study and we therefore could not control medications use. 
In this study, medications were chosen by each physician ac-
cording to each patient’s status. Nevertheless, there was no 
significant difference in medication use among the three gr-
oups. We also achieved the purpose of this study by demon-
strating improved predictions of clinical outcomes using the 
two different systems for patients with first STEMI.
Conclusion
Our study suggests an association among high plasma le-
vels of TnI, NT-proBNP, and hsCRP at admission, incomplete 
Fig. 2. Prognostic value of a multi-marker approach. The addition of biochemical markers markedly improved the prognostic utility of the model 
containing ST-segment resolution. TnI: troponin I, hsCRP: high-sensitivity C-reactive protein, NT-proBNP: N-terminal pro-B-type natriuretic 
peptide.
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ST segment resolution in patients with STEMI after PCI, 
and unfavorable clinical outcomes. Multi-directional appro-
aches to risk stratification and treatment of patients with ST-
EMI may improve the outcomes of adverse cardiac events.
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